These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28795248)

  • 1. The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.
    Roeke T; Sobral-Leite M; Dekker TJA; Wesseling J; Smit VTHBM; Tollenaar RAEM; Schmidt MK; Mesker WE
    Breast Cancer Res Treat; 2017 Nov; 166(2):435-445. PubMed ID: 28795248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer.
    Gujam FJ; Edwards J; Mohammed ZM; Going JJ; McMillan DC
    Br J Cancer; 2014 Jul; 111(1):157-65. PubMed ID: 24874480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
    Moorman AM; Vink R; Heijmans HJ; van der Palen J; Kouwenhoven EA
    Eur J Surg Oncol; 2012 Apr; 38(4):307-13. PubMed ID: 22264965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Vangangelt KMH; Tollenaar LSA; van Pelt GW; de Kruijf EM; Dekker TJA; Kuppen PJK; Tollenaar RAEM; Mesker WE
    Int J Cancer; 2018 Dec; 143(12):3194-3200. PubMed ID: 29978463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).
    Dekker TJ; van de Velde CJ; van Pelt GW; Kroep JR; Julien JP; Smit VT; Tollenaar RA; Mesker WE
    Breast Cancer Res Treat; 2013 Jun; 139(2):371-9. PubMed ID: 23709090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.
    de Kruijf EM; van Nes JG; van de Velde CJ; Putter H; Smit VT; Liefers GJ; Kuppen PJ; Tollenaar RA; Mesker WE
    Breast Cancer Res Treat; 2011 Feb; 125(3):687-96. PubMed ID: 20361254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers.
    Almangush A; Heikkinen I; Bakhti N; Mäkinen LK; Kauppila JH; Pukkila M; Hagström J; Laranne J; Soini Y; Kowalski LP; Grénman R; Haglund C; Mäkitie AA; Coletta RD; Leivo I; Salo T
    Histopathology; 2018 Jun; 72(7):1128-1135. PubMed ID: 29427291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer.
    Vangangelt KMH; Green AR; Heemskerk IMF; Cohen D; van Pelt GW; Sobral-Leite M; Schmidt MK; Putter H; Rakha EA; Tollenaar RAEM; Mesker WE
    Int J Cancer; 2020 Apr; 146(8):2296-2304. PubMed ID: 31901133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-stroma ratio has poor prognostic value in nonpedunculated T1 colorectal cancer: A multicentre case-cohort study.
    Dang H; van Pelt GW; Haasnoot KJC; Backes Y; Elias SG; Seerden TCJ; Schwartz MP; Spanier BWM; de Vos Tot Nederveen Cappel WH; van Bergeijk JD; Kessels K; Geesing JMJ; Groen JN; Borg FT; Wolfhagen FHJ; Seldenrijk CA; Raicu MG; Milne AN; van Lent AUG; Brosens LAA; Johan A Offerhaus G; Siersema PD; Tollenaar RAEM; Hardwick JCH; Hawinkels LJAC; Moons LMG; Lacle MM; Mesker WE; Boonstra JJ;
    United European Gastroenterol J; 2021 Feb; ():. PubMed ID: 33566452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROGNOSTIC VALUE OF TUMOR STROMA RATIO IN TRIPLE NEGATIVE BREAST CANCER.
    Zakhartseva LM; Yanovytska MA
    Wiad Lek; 2021; 74(3 cz 2):565-571. PubMed ID: 33843614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer.
    Sjöberg E; Augsten M; Bergh J; Jirström K; Östman A
    Br J Cancer; 2016 May; 114(10):1117-24. PubMed ID: 27115465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Stroma Ratio in ER+/HER2- Breast Cancer: Is it a Tool for Treatment Decision?
    Elmhadi C; Allaoui M; Zerrik M; Oukabli M; Tanz R; Ichou M
    Gulf J Oncolog; 2023 May; 1(42):14-21. PubMed ID: 37283255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
    Kramer CJH; Vangangelt KMH; van Pelt GW; Dekker TJA; Tollenaar RAEM; Mesker WE
    Breast Cancer Res Treat; 2019 Jan; 173(1):55-64. PubMed ID: 30302588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study.
    Dang H; van Pelt GW; Haasnoot KJ; Backes Y; Elias SG; Seerden TC; Schwartz MP; Spanier BW; de Vos Tot Nederveen Cappel WH; van Bergeijk JD; Kessels K; Geesing JM; Groen JN; Ter Borg F; Wolfhagen FH; Seldenrijk CA; Raicu MG; Milne AN; van Lent AU; Brosens LA; Offerhaus GJA; Siersema PD; Tollenaar RA; Hardwick JC; Hawinkels LJ; Moons LM; Lacle MM; Mesker WE; Boonstra JJ;
    United European Gastroenterol J; 2020 Nov; 9(4):2050640620975324. PubMed ID: 33210982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
    Joensuu H; Lehtimäki T; Holli K; Elomaa L; Turpeenniemi-Hujanen T; Kataja V; Anttila A; Lundin M; Isola J; Lundin J
    JAMA; 2004 Sep; 292(9):1064-73. PubMed ID: 15339900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.